Tag: Medication shortage

Despite persistent rumors, the global lactulose market is projected to continue its growth trajectory, according to recent market analysis. These market trends offer a direct and reassuring answer to those asking, **is lactulose being discontinued?** The simple explanation is that while a few specific brand-name formulations have been phased out, the generic version of the medication remains widely available for patients.

Reports show Zepbound is not being discontinued by its manufacturer, Eli Lilly, despite circulating online rumors. Patient concerns stem from two distinct market shifts: the recent FDA-mandated end of compounded tirzepatide availability and decisions by some large insurance pharmacy benefit managers (PBMs), such as CVS Caremark, to alter Zepbound's formulary status.

Amid a nationwide shortage of stimulant medications, a 2023 survey found that 38% of adults with ADHD had trouble filling their prescriptions [1.6.1]. If you're wondering what to do when you run out of ADHD meds, the first step is to contact your doctor and pharmacy immediately [1.2.6].

The ADHD medication shortage, which began in late 2022, continues to persist well into 2025, posing significant challenges for patients. Navigating this ongoing crisis requires careful planning and communication with healthcare providers to determine which ADHD meds are not in shortage and what alternatives may be available.

Since late 2022, many individuals with ADHD have faced significant challenges accessing their prescriptions due to persistent medication shortages. This widespread issue has particularly affected generic versions of popular stimulants, making the question 'which ADHD medication is not in shortage?' a critical concern for many patients.

According to the American Society of Health-System Pharmacists (ASHP), the United States saw a record number of active drug shortages in the first quarter of 2024, highlighting the urgency of understanding the so-called “drug exodus”. This informal term describes the significant, large-scale movements and challenges within the pharmaceutical landscape, including the discontinuation of vital medications and shifts in drug abuse patterns.